Evidence map›Paper›PMID 35126524›Full record

ArticleAdvances in hematology2022

Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study.

Mario Petrini, Gianluca Gaidano, Andrea Mengarelli, Ugo Consoli, Armando Santoro, Anna Maria Liberati, Marco Ladetto, Vincenzo Fraticelli, Attilio Guarini, Donato Mannina and 23 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 20 institutions in 1 country.

Mario PetriniSection of Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.ORCID https://orcid.org/0000-0002-1017-6961
Gianluca GaidanoDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Andrea MengarelliHematology Unit, Experimental and Clinical Oncology Department, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Ugo ConsoliDivision of Hematology, ARNAS Garibaldi, Catania, Italy.
Armando SantoroHumanitas Clinical and Research Center-IRCCS, Humanitas Cancer Center, Rozzano, Milan, Italy.
Anna Maria LiberatiAzienda Ospedaliera "Santa Maria", Terni, Italy.
Marco LadettoHematology Division, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Vincenzo FraticelliDepartment of Hematology, Gemelli Molise, Campobasso, Italy.
Attilio GuariniHematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
Donato ManninaHematology Unit, Azienda Ospedaliera, Papardo, Messina, Italy.
Paola FerrandoMedical Oncology, ASST Lecco, Lecco, Italy.
Paolo CorradiniFondazione IRCCS Instituto Nazionale dei Tumori, University of Milan, Milano, Italy.
Pellegrino MustoDepartment of Emergency and Organ Transplantation "Aldo Moro", University School of Medicine and Unit of Hematology and Stem Cell Transplantation, AOU Consorziale Policlinico, Bari, Italy.
Caterina StelitanoDivision of Haematology, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy.
Dario MarinoDepartment of Clinical and Experimental Oncology, Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Andrea CameraHematology Unit, Sant'Anna e San Sebastiano Hospital, Caserta, Italy.
Marco MurinedduHematology & Bone Marrow Transplant Unit, San Francesco Hospital, Nuoro, Italy.
Roberta BattistiniHematology Unit, AO San Camillo Forlanini, Rome, Italy.
Giuseppe CaparrottiDepartment of Haematology, ASL Caserta (CE), Hospital Moscati, Aversa (CE), Italy.
Mauro TurriniDivision of Hematology, Valduce Hospital, Como, Italy.
Luca ArcainiDivision of Hematology, Fondazione IRCCS Policlinico San Matteo and Department of Molecular Medicine, University of Pavia, Italy.
Simone SantiniASL Toscana Centro, Department of Oncology, Oncoematology Unit, Santo Stefano Hospital, Prato, Italy.
Manuela CerquetiGeneral Medicine, Hospital of Macerata, Macerata, Italy.
Andres J M FerreriDepartment of Onco-Haematology, Division of Experimental Oncology, IRCCS San Raffaele Hospital, Milan, Italy.
Nicola CantoreHematology and Hematopoietic Transplantation Unit, San G. Moscati Hospital, Avellino, Italy.
Alessandro InzoliHematology Unit, Ospedale Maggiore ASST, Crema, Italy.
Giovanni CardinaleOnco-hematology Unit, ARNAS Civico Di Cristina Benfratelli, Palermo, Italy.
Benedetto RonciHematology Unit, SS Filippo and Nicola Hospital, ASL1 Avezzano (AQ), Avezzano, Italy.
Giorgio La NasaDepartment of Medical Science and Public Health, Hematology and Transplant Center, "A. Businco" Hospital, University of Cagliari, Cagliari, Italy.
Stefano MassimiRoche S. p. A., Monza, Italy.
Gianfranco GaglioneRoche S. p. A., Monza, Italy.
Valentina BarbieroRoche S. p. A., Monza, Italy.
Maurizio MartelliDepartment of Translational and Precision Medicine, Sapienza University, Rome, Italy.
Roche (Italy) · ITAzienda Ospedaliera S.Giuseppe Moscati · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITAzienda ospedaliera "Bianchi-Melacrino-Morelli" · ITAzienda Ospedaliera Ospedale Maggiore · ITAzienda Ospedaliera Ospedali Riuniti Papardo Piemonte · ITAzienda Ospedaliera S.Maria · ITAzienda Usl Toscana Centro · ITAziende Socio Sanitarie Territoriali di LeccoCarlo Forlanini Hospital · ITHumanitas University · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Oncologico Veneto · ITIstituto Tumori Bari · ITOspedale Garibaldi · ITOspedale Sant'Anna · ITOspedale Valduce · ITSapienza University of Rome · ITUniversity of Cagliari · ITUniversity of Macerata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Subcutaneous (SC) rituximab may be beneficial in terms of convenience and tolerability, with potentially fewer and less severe administration-related reactions (ARRs) compared to the intravenous (IV) form. This report presents the results of a phase IIIb study conducted in Italy. The study included adult patients with CD20+ DLBCL or FL having received at least one full dose of IV RTX 375 mg/m

Identifiers

PMID35126524
PMCPMC8813238
OpenAlexW4210754743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.